![]() Zealand expects to have data from a Phase II, single-dose trial of ZP4207 in the second half of this year, the same window it is targeting for enrollment of the first patients in a study of the artificial pancreas. Notably, as a stable liquid glucagon analog the drug could solve one of the problems faced to date by Beta Bionics’ iLet device, raising the possibility that the partners can develop a dual-hormone system that mimics the activity of a healthy pancreas.īeta Bionics and Zealand's contributions to the combination are experimental. Zealand developed ZP4207 as a single-dose rescue treatment for severe, acute hypoglycemia, an indication in which it is already being trialled. ![]() Copenhagen, Denmark-based Zealand’s contribution to the alliance is ZP4207, part of the drug component of the planned drug-device combination product.
0 Comments
Leave a Reply. |